Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCC9 | O60706 | 16/20 | 0.54 |
| ▸ | KCNJ11 | Q14654 | 16/20 | 0.54 |
| ▸ | ABCC8 | Q09428 | 15/20 | 0.54 |
| ▸ | KCNJ8 | Q15842 | 15/20 | 0.54 |
| ▸ | IDO1 | P14902 | 2/20 | 0.37 |
| ▸ | MET | P08581 | 1/20 | 0.36 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7104751 | 0.87 | ABCC9 (0.57) | ABCC9KCNJ11ABCC8KCNJ8IDO1 | |
| SCHEMBL7016978 | 0.78 | ABCC9 (0.53) | ABCC9KCNJ11ABCC8KCNJ8IDO1 | |
| SCHEMBL7573252 | 0.77 | ABCC9 (0.55) | ABCC9KCNJ11ABCC8KCNJ8IDO1 | |
| SCHEMBL7019704 | 0.76 | ABCC9 (0.52) | ABCC9KCNJ11ABCC8KCNJ8MET | |
| SCHEMBL7103412 | 0.76 | ABCC9 (0.52) | ABCC9KCNJ11ABCC8KCNJ8IDO1 | |
| SCHEMBL7015302 | 0.76 | ABCC9 (0.52) | ABCC9KCNJ11ABCC8KCNJ8IDO1 | |
| SCHEMBL7243802 | 0.72 | ABCC9 (0.61) | ABCC9KCNJ11ABCC8KCNJ8 | |
| SCHEMBL7235474 | 0.70 | ABCC9 (0.59) | ABCC9KCNJ11ABCC8KCNJ8 | |
| SCHEMBL7101141 | 0.70 | ABCC9 (0.47) | ABCC9KCNJ11ABCC8KCNJ8POLB | |
| SCHEMBL7098825 | 0.69 | ABCC9 (0.66) | ABCC9KCNJ11ABCC8KCNJ8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1307453-A2 | DIHYDRONAPHTHYRIDINE- AND DIHYDROPYRROLOPYRIDINE-DERIVATED COMPOUNDS AS POTASSIUM CHANNEL OPENERS | ABBOTT LABORATORIES (US) | 2003-05-07 | — | — | EP | claimed |
| US-20020099070-A1 | Dihydronaphthyridine potassium channel openers | ABBOTT LABORATORIES | 2002-07-25 | — | — | US | claimed |
| WO-2002010164-A2 | DIHYDRONAPHTHYRIDINE- AND DIHYDROPYRROLOPYRIDINE-DERIVATED COMPOUNDS AS POTASSIUM CHANNEL OPENERS | ABBOTT LABORATORIES (US) | 2002-02-07 | — | — | WO | claimed |
| US-20020099070-A1 | Dihydronaphthyridine potassium channel openers | ABBOTT LABORATORIES | 2002-07-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020099070-A1 | Dihydronaphthyridine potassium channel openers | KCNH1, KCNN1, KCNJ2 | ABCC9 440/4885KCNJ11 8/4885ABCC8 645/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.